Evidence-anchored
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (daily) · Once weekly (injectable)

Semaglutide
(Ozempic, Wegovy, Rybelsus) near you

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians from the federal NPI registry, by state and city. Ask each office whether it prescribes Ozempic, Wegovy, or Rybelsus.[9]

  • Ozempic: FDA-approved for type 2 diabetes.
  • Wegovy: FDA-approved for chronic weight management.
  • Rybelsus: FDA-approved for type 2 diabetes.
total providers
24,549
as of today
01 / Find
scopeUS
Search 24,549 results →
Get matched with a provider →Tell us your state and insurance. We’ll match you with a licensed Semaglutide provider.
§ 01Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

Bar chart of Semaglutide dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg (Wegovy HD)
Semaglutide comes in 6 strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg (Wegovy HD). The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (brand-specific)
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg · 7.2 mg (Wegovy HD)
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy
§ 02Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most Semaglutide side effects are stomach and gut effects.

In Wegovy's weight trials at 2.4 mg, the most common side effects were nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Ozempic's lower diabetes doses showed lower rates.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15.8 to 44%
mild
Lowest on Ozempic 0.5 mg, highest on Wegovy 2.4 mg
Diarrhea
8.5 to 30%
mild
More frequent during dose escalation
Vomiting
5 to 24%
mild
Reduced by slower titration
Constipation
3.1 to 24%
mild
Abdominal pain
5.7 to 20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
0.4 to 2.5%
serious
Gallstones. Lowest on Ozempic 1 mg, highest on Wegovy tablets. Risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 05Cost & coverage, published, not gated
USD · monthly

What Semaglutide costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Semaglutide monthly cost by how you pay
Wegovy, pharmacy retail$1,610 to $1,788per monthBrand-name retail average, May 2026[6]
Wegovy, NovoCare self-pay$349 to $399per monthPen $349, Wegovy HD 7.2 mg $399. Pill $149 to $299
Ozempic, pharmacy retail$1,476per monthBrand-name retail average, May 2026[6]
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Commercial insurance (weight)Often deniedWegovy is on-label but frequently requires PA and is denied
Medicare Part D$0 to $100per monthType 2 diabetes covered. Wegovy for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5]
Manufacturer savings cardas low as $25per monthOzempic and Wegovy cards, commercial insurance only, up to $100 a month in savings
§ 06Semaglutide by state
50 states · 1009 towns

Find a Semaglutide provider near you.

Choose your state or town to see physicians from the federal NPI registry. Ask each office whether it prescribes Semaglutide.

Loading map

Or tap a pin on the map. 50 states, 1009 towns.

Semaglutide in California

253 towns · CA
Show all 253 towns in California
See all providers in California →

Semaglutide in Florida

101 towns · FL
Show all 101 towns in Florida
See all providers in Florida →

Semaglutide in Illinois

63 towns · IL
Show all 63 towns in Illinois
See all providers in Illinois →

Semaglutide in Texas

109 towns · TX
Show all 109 towns in Texas
See all providers in Texas →
Find a GLP-1 provider
Weight loss doctors
Physicians listed in the federal NPI registry.
Weight loss clinics
Clinics running GLP-1 programs, telehealth & in-person.
Related GLP-1 research
GLP-1s and hair loss
Why rapid loss can shed hair, and what helps it regrow.
how long GLP-1s take to work
When appetite changes show up, and when the weight curve usually follows.
oral and sublingual GLP-1 options
Pills and drops vs injections: what the evidence supports.
§ 07Frequently asked: Semaglutide

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Semaglutide is the active ingredient in three Novo Nordisk brands: Ozempic, Wegovy, and Rybelsus. No generic semaglutide is FDA-approved in the US. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (7.2 mg/week, Wegovy HD). Insurers treat the brands as separate drugs.[1]